1. Home >
  2. M&A >
  3. Divestiture >
  4. Belgium >
  5. GSK Acquires UCB - Pharmaceutical Brands

M&A Deal Summary

GSK Acquires UCB - Pharmaceutical Brands

On January 23, 2009, GSK acquired life science company UCB - Pharmaceutical Brands for 515M EUR

Acquisition Highlights
  • This is GSK’s 11th transaction in the Life Science sector.
  • This is GSK’s 15th largest (disclosed) transaction.
  • This is GSK’s 1st transaction in Belgium.

M&A Deal Summary
Date 2009-01-23
Target UCB - Pharmaceutical Brands
Sector Life Science
Buyer(s) GSK
Deal Type Divestiture
Deal Value 515M EUR

Target

UCB - Pharmaceutical Brands

Belgium
UCB - Pharmaceutical Brands include Keppra for the treatment of epilepsy and Xyzal and Zyrtec for the treatment of allergic rhinitis. The acquired products will be sold in multiple territories. Asia Pacific territories include Malaysia, Taiwan, Thailand and Vietnam. Middle Eastern territories include Egypt, Pakistan, Saudi Arabia and United Arab Emirates. African territories include South Africa. Latina territories include Argentina and Chile. Territories excluded are China, South Korea, India, Australia, Mexico, Brazil and Malta.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees68,629
Revenue 31.4B GBP (2024)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 13 of 35
Sector: Life Science M&A 11 of 28
Type: Divestiture M&A Deals 3 of 7
Country: Belgium M&A 1 of 1
Year: 2009 M&A 1 of 5
Size (of disclosed) 15 of 31
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-10-29 Genelabs Technologies

Redwood City, California, United States

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus.

Buy $57M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-04-20 Stiefel Laboratories

Research Triangle Park, North Carolina, United States

Stiefel Laboratories, Inc. is enthusiastically committed to advancing dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates.

Buy $2.9B
Mergr

Solution for

Product

Company

Legal